Skip to content
10-Q

Quarterly Report

IMMIX BIOPHARMA, INC. IMMX

0001641172-25-022829

← back to feed
Filed
Aug 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Aug 1, 2025 28.83M sh
Shares Diluted Q2 2025 · Jun 30, 2025 29.98M sh
Shares Diluted Q2 2025 · Jun 30, 2025 29.84M sh
Shares Diluted Q2 2025 · Jun 30, 2024 28.79M sh
Shares Diluted Q2 2025 · Jun 30, 2024 27.07M sh
Capex Q2 2025 · Jun 30, 2025 $195.34K
Capex Q2 2025 · Jun 30, 2024 $398.99K
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$6.99M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$9.08M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $11.64M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $17.68M
Current Liabilities Q2 2025 · Jun 30, 2025 $10.01M
Current Liabilities Q2 2025 · Dec 31, 2024 $8.69M
Total Liabilities Q2 2025 · Jun 30, 2025 $10.98M
Total Liabilities Q2 2025 · Dec 31, 2024 $9.7M
Current Assets Q2 2025 · Jun 30, 2025 $12.33M
Current Assets Q2 2025 · Dec 31, 2024 $20.2M
Total Assets Q2 2025 · Jun 30, 2025 $15.64M
Total Assets Q2 2025 · Dec 31, 2024 $22.95M
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.22
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.37
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.15
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.36
Eps Basic Q2 2025 · Jun 30, 2025 −$0.22
Eps Basic Q2 2025 · Jun 30, 2025 −$0.37
Eps Basic Q2 2025 · Jun 30, 2024 −$0.15
Eps Basic Q2 2025 · Jun 30, 2024 −$0.36
Sga Expense Q2 2025 · Jun 30, 2025 $2.75M
Sga Expense Q2 2025 · Jun 30, 2025 $5.45M
Sga Expense Q2 2025 · Jun 30, 2024 $2.48M
Sga Expense Q2 2025 · Jun 30, 2024 $4.82M
Rd Expense Q2 2025 · Jun 30, 2025 $3.97M
Rd Expense Q2 2025 · Jun 30, 2025 $5.95M
Rd Expense Q2 2025 · Jun 30, 2024 $2.22M
Rd Expense Q2 2025 · Jun 30, 2024 $5.47M
Net Income Q2 2025 · Jun 30, 2025 −$6.62M
Net Income Q2 2025 · Jun 30, 2025 −$11.17M
Net Income Q2 2025 · Jun 30, 2024 −$4.39M
Net Income Q2 2025 · Jun 30, 2024 −$9.65M
Operating Income Q2 2025 · Jun 30, 2025 −$6.72M
Operating Income Q2 2025 · Jun 30, 2025 −$11.4M
Operating Income Q2 2025 · Jun 30, 2024 −$4.7M
Operating Income Q2 2025 · Jun 30, 2024 −$10.29M
Revenue Q2 2025 · Dec 8, 2022 $20M